Stock DNA
Pharmaceuticals & Biotechnology
CHF 224,339 Million ()
17.00
NA
0.00%
0.29
36.86%
6.36
Revenue and Profits:
Net Sales:
11,608 Million
(Quarterly Results - Jun 2025)
Net Profit:
3,324 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.73%
0%
6.73%
6 Months
7.58%
0%
7.58%
1 Year
19.8%
0%
19.8%
2 Years
22.77%
0%
22.77%
3 Years
31.06%
0%
31.06%
4 Years
49.09%
0%
49.09%
5 Years
36.48%
0%
36.48%
Novartis AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.09%
EBIT Growth (5y)
9.15%
EBIT to Interest (avg)
14.48
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.60
Tax Ratio
13.85%
Dividend Payout Ratio
67.17%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
19.87%
ROE (avg)
25.50%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
6.58
EV to EBIT
16.13
EV to EBITDA
11.99
EV to Capital Employed
4.55
EV to Sales
5.18
PEG Ratio
0.97
Dividend Yield
NA
ROCE (Latest)
28.21%
ROE (Latest)
39.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 15 Foreign Institutions (0.08%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
11,608.20
11,896.10
-2.42%
Operating Profit (PBDIT) excl Other Income
4,822.00
5,153.80
-6.44%
Interest
238.70
242.70
-1.65%
Exceptional Items
-296.50
-44.00
-573.86%
Consolidate Net Profit
3,323.70
3,244.40
2.44%
Operating Profit Margin (Excl OI)
332.90%
346.30%
-1.34%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.42% vs 3.08% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 2.44% vs 31.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
44,312.50
40,834.70
8.52%
Operating Profit (PBDIT) excl Other Income
18,930.80
18,102.40
4.58%
Interest
913.30
784.50
16.42%
Exceptional Items
-1,696.20
-3,236.90
47.60%
Consolidate Net Profit
10,514.30
7,703.20
36.49%
Operating Profit Margin (Excl OI)
306.60%
261.20%
4.54%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.52% vs 1.30% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 36.49% vs 33.34% in Dec 2023
About Novartis AG 
Novartis AG
Pharmaceuticals & Biotechnology
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Coordinates 
Company Details
Lichtstrasse 35 , BASEL None : 4056
Registrar Details






